Monday, May 18, 2020 8:48:12 AM
Rock, I agree with you to a point. I don't think there will be a vaccine within 12-18 months. However, I do believe there will be a vaccine eventually. As a layperson, the only real comparison for me is the flu. There is a flu vaccine, it works in many cases, but not all cases, because the virus mutates. We know that COVID-19 mutates, and that there are stages to the disease. If you saw Dr. Yang's presentation, you know what I'm referring to. You are right, Cytokine storm is the constant in the moderate to severe cases.
Maybe my post did not adequately reflect my optimism for LERO. Rantes and Cytokine storm are new terms for most of us as well. Dr. Yang showed that LERO reduces the viral load in addition to calming the Cytokine storm. If the current Phase 2/3 trial and this new combo trial with REM shows safety, efficacy, in addition to statistical significance, LERO or LERO/REM will be the go-to mitigation for COVID-19 for an undetermined period of time.
Not to be ignored is that Cytokine storm occurs in other diseases. I'm sure trials will be initiated, if success continues to be demonstrated in COVID-19. I hope you had opportunity to listen to Dr. Lalezari's comments. I never heard any doctor speak in those terms. Essentially he said that Leronlimab was a gift from heaven dropped into our laps. However, as you know better than most of us, we still need to be cautiously optimistic, as potential patients, as loved ones of potential patients, and investors. At this point, IMO, REM needs LERO, more than LERO needs REM.
Maybe my post did not adequately reflect my optimism for LERO. Rantes and Cytokine storm are new terms for most of us as well. Dr. Yang showed that LERO reduces the viral load in addition to calming the Cytokine storm. If the current Phase 2/3 trial and this new combo trial with REM shows safety, efficacy, in addition to statistical significance, LERO or LERO/REM will be the go-to mitigation for COVID-19 for an undetermined period of time.
Not to be ignored is that Cytokine storm occurs in other diseases. I'm sure trials will be initiated, if success continues to be demonstrated in COVID-19. I hope you had opportunity to listen to Dr. Lalezari's comments. I never heard any doctor speak in those terms. Essentially he said that Leronlimab was a gift from heaven dropped into our laps. However, as you know better than most of us, we still need to be cautiously optimistic, as potential patients, as loved ones of potential patients, and investors. At this point, IMO, REM needs LERO, more than LERO needs REM.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
